ZURA

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 11.67 USD with a low forecast of 2.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Zura Bio Ltd revenue for the last quarter amounts to -19.52M USD, increased 1.04 % YoY.

Zura Bio Ltd. EPS for the last quarter amounts to -15476000.00 USD, increased 173.14 % YoY.

Zura Bio Ltd (ZURA) has 30 emplpoyees as of January 07 2026.

Today ZURA has the market capitalization of 314.06M USD.